PET/CT Bests Biopsy in Lymphoma Progression to Bone Marrow

August 2, 2013

Examination with 18F-FDG PET/CT can better determine the level of bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) than can bone marrow biopsy, according to a study published in The Journal of Nuclear Medicine.

French researchers performed a retrospective study of 133 patients diagnosed with DLBCL between June 2005 and October 2011. To determine if there was bone marrow involvement, all the patients underwent whole-body 18F-FDG PET/CT and a bone marrow biopsy from the iliac crest before any treatment. Median follow-up was 24 months, ranging from one to 67 months.